ADAMTSL4

Across TCGA pan-cancer cohorts, ADAMTSL4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ADAMTSL4 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ADAMTSL4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADAMTSL4 expression acts as an unfavorable survival marker.

CCRCC, COAD, and GBM are the cancer types where ADAMTSL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.549	0.888	<.001	76	view →
COAD	DFS	Median	II,III,IV	0.879	1.000	.019	30	view →
GBM	OS	Tertile	All	0.701	0.940	.001	22	view →
HNSC	OS	Median	II,III,IV	0.952	1.000	.016	7	view →
LUAD	DFS	Median	II,III,IV	0.233	0.779	.006	6	view →
LSCC	OS	Tertile	II,III,IV	0.878	1.000	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ADAMTSL4–CCRCC (DFS)

Open the CCRCC breakdown →